» Articles » PMID: 17503754

HIV-1 Drug Resistance Surveillance Using Dried Whole Blood Spots

Overview
Journal Antivir Ther
Publisher Sage Publications
Date 2007 May 17
PMID 17503754
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Field-friendly methods for HIV drug resistance (HIVDR) surveillance in resource-limited regions are urgently needed. Despite evidence that dried blood spots (DBS) are suitable for HIV serology, viral load and CD4+ T-cell enumeration, no study has evaluated DBS for HIVDR genotyping. We assessed the feasibility of genotyping HIV-1 from field-collected DBS stored under challenging environmental conditions.

Methods: We prospectively collected specimens from newly diagnosed, treatment-naive HIV-positive subjects in Mexico. Whole blood was spotted onto filter cards, air dried at ambient temperature and stored with desiccant at 37 degrees C and 85% humidity for 3 months. Genotypes obtained from DBS-extracted nucleic acids using an in-house nested reverse transcription-PCR method were compared to genotypes derived from matched plasma.

Results: Genotypes from 103 phylogenetically matched plasma and DBS were compared. In total, 90.1% of all DBS specimens could be amplified in either the region of HIV protease or the region of reverse transcriptase. Failure to amplify from DBS did not correlate with low plasma viral loads. Between paired specimens, the median nucleotide similarity was 99.95%. In the nine specimens with drug resistance mutations, all differences between pairs were partial discordances. Mutations identified in plasma were found in the majority of replicate DBS amplifications.

Conclusion: The results suggest that genotypes obtained from DBS are equivalent to those from plasma. DBS are a promising public health tool for HIVDR surveillance of treatment-naive subjects, especially in regions where specimens might be exposed to severe environmental conditions and where logistical difficulties could prevent timely specimen processing. More studies are needed to validate DBS for patient monitoring.

Citing Articles

HIV-1 drug resistance genotyping success rates and correlates of Dried-blood spots and plasma specimen genotyping failure in a resource-limited setting.

Omooja J, Bbosa N, Lule D, Nannyonjo M, Lunkuse S, Nassolo F BMC Infect Dis. 2022; 22(1):474.

PMID: 35581555 PMC: 9112432. DOI: 10.1186/s12879-022-07453-9.


HIV-2 Drug Resistance Genotyping from Dried Blood Spots.

Raugi D, Nixon R, Leong S, Faye K, Diatta J, Sall F J Clin Microbiol. 2020; 59(1).

PMID: 33055182 PMC: 7771475. DOI: 10.1128/JCM.02303-20.


Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations.

Avila-Rios S, Parkin N, Swanstrom R, Paredes R, Shafer R, Ji H Viruses. 2020; 12(6).

PMID: 32516949 PMC: 7354449. DOI: 10.3390/v12060617.


Prevalence of viral load suppression, predictors of virological failure and patterns of HIV drug resistance after 12 and 48 months on first-line antiretroviral therapy: a national cross-sectional survey in Uganda.

Ssemwanga D, Asio J, Watera C, Nannyonjo M, Nassolo F, Lunkuse S J Antimicrob Chemother. 2020; 75(5):1280-1289.

PMID: 32025714 PMC: 7177494. DOI: 10.1093/jac/dkz561.


High throughput sequencing of T-cell receptor repertoire using dry blood spots.

Wu S, Pan W, Liu H, Byrne-Steele M, Brown B, Depinet M J Transl Med. 2019; 17(1):47.

PMID: 30777078 PMC: 6379990. DOI: 10.1186/s12967-019-1796-4.